TFF Pharmaceuticals to Participate in the 35th Annual Roth Conference
TFF Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that CEO Harlan Weisman will partake in a Fireside Chat at the 35th Annual Roth Conference from March 12-14, 2023, at The Ritz Carlton, Laguna Niguel, CA. Weisman will discuss the company's patented Thin Film Freezing technology, which enhances drug delivery and bioavailability. The chat is scheduled for March 13, 2023, at 10:30 AM PT, hosted by Jonathan Aschoff of ROTH Capital Partners. TFF Pharmaceuticals aims to reformulate medicines into dry powder forms, improving efficacy and safety. The event will feature one-on-one meetings with management and a replay accessible for 90 days on their website.
- None.
- None.
FORT WORTH, Texas, March 06, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that CEO Harlan Weisman, M.D. will be participating in a Fireside Chat at the 35th Annual Roth Conference being held in-person at The Ritz Carlton, Laguna Niguel in Dana Point on March 12-14, 2023. Company management will also be participating in one-on-one meetings throughout the conference.
35th Annual Roth Conference – March 12-14, 2023
| Format: | Fireside Chat | |
| Date/Time: | Monday, March 13, 2023 at 10:30 AM PT | |
| Host: | Jonathan Aschoff, PhD, Senior Research Analyst, ROTH Capital Partners | |
| Participant: | Harlan Weisman, M.D., Chief Executive Officer | |
| Location: | The Ritz Carlton, Laguna Niguel in Dana Point, CA | |
| Webcast Link: | Register here |
Please contact your Roth representative to schedule one-on-one meetings with the management team during the conference. A replay of the fireside chat will be available for 90 days on the Events section of the TFF website.
TFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology
TFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The Thin Film Freezing process is a particle engineering process designed to generate dry powder particles with advantageous properties for inhalation, as well as parenteral, nasal, oral, topical and ocular routes of administration. The process can be used to engineer powders for direct delivery to the site of need, circumventing challenges of systemic administration and leading to improved bioavailability, faster onset of action, and improved safety and efficacy. The ability to deliver therapies directly to the target organ, such as the lung, allows TFF powders to be administered at lower doses compared to oral drugs, reducing unwanted toxicities and side effects. Laboratory data suggests the aerodynamic properties of the powders created by Thin Film Freezing can deliver as much as
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety, and stability. The company’s versatile Thin Film Freezing (TFF) technology platform has broad applicability to convert most any drug, including vaccines, small and large molecules, and biologics, into an elegant dry powder highly advantageous for inhalation, with improved absorption so drugs can also be delivered to the eyes, nose and topically to the skin. TFF has two lead drug candidates in the clinic: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder, and continues to expand its pipeline by collaborating with a broad array of pharmaceutical companies, academic institutions, and government partners to revolutionize healthcare around the globe. The TFF Platform is protected by 120+ patents issued or pending in the U.S. and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.
Safe Harbor
This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including, the benefits of the Company’s TFF platform and the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to successfully conclude clinical testing or obtain pre-market approval of any of its dry powder product candidates, (ii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (iv) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (vi) those other risks disclosed in the section “Risk Factors” included in the Company’s Prospectus Supplement filed with the SEC on November 18, 2022. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.
TFF Contacts:
Corporate Contact:
Bill Begien
VP of Investor Relations
TFF Pharmaceuticals, Inc.
c (617) 842-2222
bbegien@tffpharma.com
Investor Relations Contact:
Corey Davis, Ph.D.
LifeSci Advisors
(212) 915-2577
cdavis@lifesciadvisors.com
Media Contact:
Raena Mina, Ph.D.
LifeSci Communications
rmina@lifescicomms.com
Source: TFF Pharmaceuticals, Inc.
FAQ
What is TFF Pharmaceuticals' participation in the 35th Annual Roth Conference?
When is TFF Pharmaceuticals' Fireside Chat scheduled?
Who is hosting TFF Pharmaceuticals' Fireside Chat at the Roth Conference?
Where will the 35th Annual Roth Conference take place?
How can I access the replay of TFF Pharmaceuticals' Fireside Chat?
